
Clavis Pharma ASA
OSL:CLAVIS ISIN:NO0010308240
News
Clavis Pharma ASA (OSL:CLAVIS) "Three products in clinical development" Oslo, Norway, October 23, 2008
Clavis Pharma ASA (OSL:CLAVIS) Clavis Pharma ASA (CLAVIS) will present its third quarter 2008 results on Thursday 23 October 2008 at Hotel Continental, Stortingsgaten 24/26 (Meeting Room 4).
Clavis Pharma ASA (OSL:CLAVIS) Oslo, Norway, 7 October 2008
Clavis Pharma ASA (OSL:CLAVIS) Oslo, Norway, September 15, 2008 Clavis Pharma ASA (OSE: CLAVIS) announced today that promising results from its Intravenous CP-4126 Phase I study in patients with solid tumours have been presented at the European Society for Medical Oncology (ESMO) Meeting 2008. The presentation was held on 13 September.
Clavis Pharma ASA (OSL:CLAVIS) Clinical development of ELACYT in haematology expanded
Clavis Pharma ASA (OSL:CLAVIS) Oslo, Norway, 19 August 2008
Clavis Pharma ASA Oslo, Norway, 29 July 2008 Clavis Pharma (OSE: CLAVIS) announced today that it is amending its clinical program for ELACYT following an evaluation of all clinical data available for ELACYT(TM), both in haematology and solid tumours.
Clavis Pharma ASA Clavis Pharma Receives US Orphan Drug Designation for ELACYT(TM) Oslo, Norway, June 25, 2008
4,023 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 7) (Last 30 Days: 33) (Since Published: 4023)